Jeffries said that BioCryst Pharmaceuticals Inc.'s (Nasdaq: BCRX) upbeat trial results for its BCX4161 hereditary angioedema treatment bode well for Dyax Corp.'s (Nasdaq: DYAX) CX-2930. Shares of BioCryst climbed 98 cents to close at $9.99 while Dyax stock leaped $1.81 to close at $8.41.
Jeffries optimistic about Dyax
May 27, 2014 at 16:46 PM EDT
